RCM
ARTV

Revelation Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Revelation Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93M Hold
299,311
– – 2.86% 2
2025
Q4 		$1.28M Buy
+299,311
New +$1.13M 1.54% 2

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Revelation Capital Management's ARTV Position: Q1 2026 in Review

Revelation Capital Management held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 299,311 shares worth $1.93M. The position accounts for 2.86% of the portfolio, ranked #2.

Revelation Capital Management first reported a position in ARTV in Q4 2025 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Revelation Capital Management held 299,311 shares of Artiva Biotherapeutics worth $1.93M as of Q1 2026.
  • Revelation Capital Management left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up 2.86% of Revelation Capital Management's portfolio in Q1 2026, its #2 holding.
  • Revelation Capital Management first reported a position in Artiva Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Revelation Capital Management's 13F filing for Q1 2026, filed 15 May 2026.